SGLT2 inhibitors have been shown to improve cardiovascular outcomes in patients with T2DM by reducing the risk of major adverse cardiovascular events and heart failure hospitalizations and have demonstrated renoprotective effects by slowing the progression of diabetic kidney disease [3,4,5,6]. Here, SLC5A2 is linked to heart failure.